PCV2 is considered the main pathogen of porcine circovirus diseases and porcine circovirus-associated diseases (PCVD/PCVAD). However, the exact mechanism underlying PCVD/PCVAD is currently unknown. Mouse models of PCV2 are valuable experimental tools that can shed light on the pathogenesis of infection and will enable the evaluation of antiviral agents and vaccine candidates. In this review, we discuss the current state of knowledge of mouse models used in PCV2 research that has been performed to date, highlighting their strengths and limitations, as well as prospects for future PCV2 studies. To date, the exact mechanism of PCVD/PCVAD is currently unknown, and there are no approved effective therapeutics for PCV2 infection. Although several commercial vaccines based on PCV2a are effective in protecting pigs against challenge with PCV2a, 9 they cannot protect pigs against the PCV2b genotype that is prevalent worldwide, as well as other PCV2 genotypes. Moreover, some PCV2-infected pigs can develop severe disease while many pigs in the same herd and farm remain asymptomatic. Therefore, an in vivo infection model is critical for understanding the pathogenesis during PCV2 infection and coinfection with other swine pathogens.
| INTRODUCTION
Porcine circovirus (PCV) belongs to the genus Circovirus of the family Circoviridae and contains a single-stranded 1.7-kb circular DNA. [1] [2] [3] [4] There are two types of PCV: porcine circovirus type 1 (PCV1) and porcine circovirus type 2 (PCV2). PCV1 is nonpathogenic, whereas PCV2 is considered the main pathogen of porcine circovirus diseases and porcine circovirus-associated diseases (PCVD/PCVAD), including a number of different syndromes and diseases in pigs, such as postweaning multisystemic wasting syndrome (PMWS), porcine respiratory disease complex (PRDC), reproductive failure, granulomatous enteritis, necrotizing lymphadenitis, exudative epidermitis, and congenital tremor. 1, [4] [5] [6] Furthermore, many of the syndromes associated with PCVD/PCVAD are a result of coinfection with PCV2 and other swine pathogens, such as porcine reproductive and respiratory syndrome virus (PRRSV), porcine parvovirus (PPV), Mycoplasma hyopneumoniae, bacterial septicemia or pneumonia, and swine influenza virus (SIV). 4, [7] [8] [9] To date, the exact mechanism of PCVD/PCVAD is currently unknown, and there are no approved effective therapeutics for PCV2 infection. Although several commercial vaccines based on PCV2a are effective in protecting pigs against challenge with PCV2a, 9 they cannot protect pigs against the PCV2b genotype that is prevalent worldwide, as well as other PCV2 genotypes. Moreover, some PCV2-infected pigs can develop severe disease while many pigs in the same herd and farm remain asymptomatic. Therefore, an in vivo infection model is critical for understanding the pathogenesis during PCV2 infection and coinfection with other swine pathogens.
The mouse has been widely used as an infection model to elucidate the in vivo behaviors of virus-host interactions. [10] [11] [12] Although some research groups have reported that mouse models provide only limited utility in advancing the understanding of PCVD/ PCVAD [13] [14] [15] and that the ORF3 protein has very limited pathogenicity in its primary host, 16 mouse models are useful for the study of cellular responses to PCV2 in the context of an animal host. The purpose of this review is to discuss the current state of knowledge
of mouse models used in PCV2 research that has been performed to date, highlighting their strengths and limitations as well as prospects for future PCV2 studies.
| PATHOGEN ESIS OF PCVIN MICE
PCV2 has been shown to replicate and spread in BALB/c 14, [17] [18] [19] and Kunming mice. 20, 21 PCV2 nucleic acids can be detected in lymphoid tissues, the liver, epithelial cells, and the thymus. 17 Furthermore, the virus can be transmitted directly from mouse to mouse by contact, and it causes vertical infection through the placenta. 20, [22] [23] [24] 
41-44
Virus-like particles (VLPs) constitute versatile tools in vaccine development due to their favorable immunological characteristics, such as their size, repetitive surface geometry, and ability to induce both innate and adaptive immune responses. 45 The full-length PCV2
Cap protein expressed in E. coli can self-assemble into VLPs 25-30 nm in diameter that can stimulate specific immune responses to PCV2 in mice. 46 Aguilera and colleagues constructed chimeric VLPs using papaya ringspot virus (PRSV) as an epitope presentation scaffold. 47 They found that the chimeric VLPs induced high levels of immunoglobulin G against PCV2 epitopes in immunized BALB/c mice. 47 Furthermore, VLPs can be used as transfer vehicles carrying foreign proteins or antigenic epitopes to produce chimeric VLPs. 48 The GP5 epitope B from PRRSV was inserted into loop CD of the PCV2 Cap, resulting in chimeric PCV2 VLPs. 48 The results showed that chimeric PCV2 VLPs induced strong humoral (neutralizing antibodies against PCV2 and PRRSV) and cellular immune responses in mice. 48 The somatostatin (SS) gene was fused to the 3 0 -terminal of the Cap protein, self-assembled into VLPs in Sf9 cells, and immunized into mice, followed by challenge with PCV2. 49 The results demonstrated that body weight gain and anti-SS antibody in the rCap-SS group was obviously higher than that of the control group 28 and 42 days postinoculation (dpi). 49 In addition to vaccines, different adjuvants have also been investigated for the production of antibodies from PCV2 vaccine-immunized mice. Inactivated PCV2 vaccine conjugated with chitosan oligosaccharide, Lycium barbarum polysaccharides or Epimedium polysaccharide-propolis flavone liposomes can remarkably enhance both humoral and cellular immunity against PCV2 by promoting T lymphocyte proliferation, initiating a Th1/Th2 response, and increasing the production of PCV-2-specific antibodies and the secretion of inflammatory cytokines in mice. [50] [51] [52] These natural polysaccharides from plant, bacterial, yeast, and synthetic sources are safer and biodegradable, without the tissue deposits observed for aluminum adjuvants. 53 Moreover, adjuvant cytokines or DNA, such as porcine CD40 ligand (CD40L), granulocyte-macrophage colony-stimulating factor (GM-CSF), ubiquitin, the N-terminus of porcine heat shock protein Gp96, and a CpG motif could also significantly enhance humoral immune responses, PCV2-specific antibody titer, and neutralizing activities in mice. [54] [55] [56] [57] Additionally, a CpG motif can also reduce immune organ damage in mice, 55 while CD40L and GM-CSF could synergistically enhance the protective immune responses of PCV2 adenovirus vaccine. 54 
| EVALUATIN G PROTECTIVE CHEMICALS AND ANTIVIRAL AGENTS IN MICE
To determine whether dietary supplementation with protective chemicals or antiviral agents can offer protection against virus infection, mice were treated with different chemicals or antivirals, followed by PCV2 infection. The results showed that dietary supplementation with aluminosilicate, 58 selenium yeast, 59 arginine, 60 proline, 61 and L-glutamine 62,63 can enhance the immune system and confer mice with antiviral protection against PCV2. 4 Moreover, dietary supplementation with arginine, L-glutamine, and proline can also improve pregnancy outcomes in PCV2-infected mice.
4,61-63
Previously, we found that statin, an inhibitor of HMG CoA reductase (HMGCR), significantly stimulated PCV2 replication in vitro. 64 Using the mouse models, we further evaluated the effect of statin on PCV2 infection in mice. The results showed that mice treated with atorvastatin during PCV2 infection had reduced body weights. 18 PCV2 antigens were mainly immunolocalized to the cytoplasms and plasma membranes of cells in the lymph nodes of PCV2-inoculated mice. 18 These results further confirmed that HMGCR is negatively associated with PCV2 infection. 18, 64 Furthermore, CD44 has been reported to play an antiviral role in response to PCV2 infection. 34 Therefore, the critical role of these chemicals against PCV2 infection is to regulate immune function and inhibit oxidative stress in mice. 
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